Bristol R&D Success Shows Link Between Licensing And First-Cycle Approval
Executive Summary
Bristol-Myers Squibb's heavy reliance on in-licensing products in the first half of the decade appears to have paid off with a high number of new molecular entity submissions and a relatively strong first-cycle approval record
You may also be interested in...
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development
Bristol Feels Plavix And Pravachol Pain; Does Relief Lie In Conservative R&D?
As Bristol-Myers Squibb prepares to weather patent losses for its two top-selling products - Pravachol and Plavix - the firm is sticking by a conservative approach to research & development
Mid-Phase III Meetings Suggested As Way To Increase First-Cycle Approvals
FDA should consider conducting mid-Phase III meetings with drug sponsors as a way to improve the likelihood of approving an application during the first review cycle, a report by Booz Allen Hamilton recommends